NCT04296019招募中2 期
A Randomized, Open-label, Multicenter, Phase II Clinical Study Evaluating the Efficacy and Safety of Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2021年2月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This study was a randomized, controled, multicenter, phase II clinical study evaluating the efficacy and safety of fruquintinib as a maintenance therapy following first-line treatment for metastatic colorectal cancer. This study will include the patients with confirmed unresectable metastatic left-sided colon cancer with RAS mutation or right-sided colon cancer who achieved stable disease (SD) or partial response (PR) or complete response (CR) via palliative first-line treatment. It's expected to include 110 patients and they will be randomly stratified at 2:1 into fruquintinib group and observation group based on whether bevacizumab is used and the primary tumor site, using the Interactive Network Response System (IWRS). The random No. corresponds to the respective patient. The enrollment time is expected to be 18 months, followed up for 24 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-75 years old (including 18 and 75 years);
- •Eastern Cooperative Oncology Group-performance score (ECOG PS) 0 or 1;
- •Estimated survival ≥ 6 months;
- •Histologically and/or cytologically confirmed metastatic left-sided colon cancer with RAS mutation or right-sided colon cancer, having unresectable metastatic or recurrent foci;
- •Having received first-line systemic anti-tumor therapy for mCRC (chemotherapeutic drugs may include fluorouracil, oxaliplatin, irinotecan, such as XELOX, FOLFOX, FOLFIRI, and can combine or not combine with bevacizumab); achieving RECIST1.1-assessed SD (stable disease) or PR (partial response) or CR (complete response) after 18-24 weeks of first-line treatment.
- •UCG suggesting left ventricular ejection fraction ≥50%;
- •Having fully understood and voluntarily signed the informed consent.
排除标准
- •Absolute neutrophil count (ANC) <1.5×109/L, or platelet count <80×109/L, or hemoglobin < 9g/dL; it's not allowed to perform blood transfusion within 2 week before enrollment to meet the inclusion criteria;
- •Serum total bilirubin > 1.5 × upper limit of normal (ULN); > 2.5 × ULN for patients with hepatic metastases;
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 × ULN, or > 5 × ULN for patients with hepatic metastases;
- •Serum creatinine > 1.5 × upper limit of normal (ULN), or creatinine clearance < 50mL / min (calculated using Cockcroft-Gault formula);
- •Partial prothrombin time (APTT) or prothrombin time (PT) > 1.5 times ULN (based on the normal value in the clinical study center);
- •Clinically significant electrolyte abnormalities;
- •Urine protein 2+ or above, or 24-hour urinary protein quantity ≥ 1.0g / 24h;
- •Subjects with dysphagia or known drug absorption disorders;
- •Presence of brain metastasis or leptomeningeal metastasis;
- •The toxicity of previous anticancer treatment has not yet reduced to (NCI CTC AE) level 1, excluding alopecia and oxaliplatin-induced neurotoxicity ≤ 2); patients haven't not fully recovered from previous surgery or less than 4 weeks elapsed since previous anticancer treatment or surgery;
- •Patients have clinically detectable second primary malignant tumors at enrollment, or have other malignant tumors (except for well-treated basal cell carcinoma or cervical carcinoma in situ) in the past 5 years;
- •Patients have clinically uncontrolled active infections such as acute pneumonia, hepatitis B or hepatitis C activity (previous history of hepatitis B infection, whether or not under medication control, HBV DNA ≥ 104 copies or ≥ 2000 IU/ml);
- •Patients have hypertension that cannot be controlled by a single drug. That is, after single drug treatment, systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg;
- •Patients currently have digestive tract diseases such as duodenal ulcer, ulcerative colitis, intestinal obstruction or other conditions that may cause gastrointestinal bleeding or perforation at the discretion of the investigator; or patients have undergone surgery for intestinal perforation and intestinal fistula but was uncured.
- •Patients have a history of arterial thrombosis or deep vein thrombosis within 6 months prior to enrollment, or patients have bleeding tendency or bleeding history within the 2 months before enrollment, regardless of severity;
- •Patients have a stroke or transient ischemic attack within 12 months prior to enrollment;
- •Skin wounds, surgical sites, trauma site, severe mucosal ulcers or fractures haven't completely healed yet.
- •Patients have acute myocardial infarction, severe/unstable angina, coronary artery bypass grafting or NYHA Class II/more severe cardiac insufficiency within 6 months prior to enrollment;
- •Pregnant or lactating women; or women with potentiality of childbearing have a positive pregnancy test result before the first dose;
- •Patients have any clinical or laboratory abnormalities or compliance problems so that the investigator believes that they are not suitable to participate in this clinical study;
- •Patients have serious psychological or mental abnormalities;
研究组 & 干预措施
Fruquintinib
Experimental
Patients who achieved stable disease (SD) or partial response (PR) or complete response (CR) following palliative first-line treatment will receive maintenance therapy with fruquintinib.
干预措施: Fruquintinib (Drug)
结局指标
主要结局
PFS
时间窗: 24 months after the last subject participating in
progression-free survival (PFS) is defined as time from randomization to disease progression.
次要结局
- OS(36 months after the last subject participating in)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(1 month after the last administration of fruquintinib)
研究者
Tianshu Liu
Director of Oncology Department
Shanghai Zhongshan Hospital
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCHepatocellular Carcinoma (HCC)NCT03516071Zai Lab (Shanghai) Co., Ltd.90
Unknown
2 期
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOCFallopian Tube CancerPeritoneal CancerEpithelial Ovarian CancerNCT04983550CSPC ZhongQi Pharmaceutical Technology Co., Ltd.126
已完成
2 期
Lapatinib in Combination With VinorelbineCancerNCT01013740Novartis Pharmaceuticals112
Unknown
2 期
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer PatientsTriple Negative Breast CancerNCT04502680The First Affiliated Hospital with Nanjing Medical University100
Unknown
2 期
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical ResectionHepatocellular Carcinoma (HCC)NCT05213637Chinese PLA General Hospital430